Celgene Corp. has extended its strategic collaboration with PharmAkea Inc. to leverage PharmAkea’s drug discovery platform and small-molecule therapies targeting fibrotic diseases.   Celgene will pay $9 million to extend the collaboration for 9 months. PharmAkea is currently conducting a Phase I SAD and MAD trial, as well as toxicology studies that will enable Phase II trials on its lead program, a small molecule LOXL2 inhibitor. The company is also conducting IND-enabling studies for a ...